AXSM – axsome therapeutics, inc. (US:NASDAQ)

News

Axsome Therapeutics Highlights Auvelity Momentum, 600-Rep Sales Push, and April 30 ADA PDUFA at Oppenheimer Conf. [Yahoo! Finance]
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics (AXSM) was upgraded by Wolfe Research to "strong-buy".
Axsome Therapeutics (NASDAQ:AXSM) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Axsome Therapeutics (NASDAQ:AXSM) was given a new $207.00 price target on by analysts at Morgan Stanley.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com